Characteristic | N = 11 |
---|---|
Time since diagnosis of sarcoidosis (years), mean (SD) | 23.7 (12.1) |
Time since confirmation of PH (years), mean (SD) | 5.5 (3.8) |
Method used to confirm PH, n (%) | |
Right heart catheterization | 9 (82) |
Echocardiogram only | 2 (18) |
Current treatment for SAPHa, n (%) | |
Anticoagulants | 2 (18) |
Calcium channel blockers | 1 (9) |
Diuretics | 4 (36) |
Endothelin receptor antagonists | 6 (55) |
Phosphodiesterase type 5 inhibitors | 5 (45) |
Oxygen | 4 (36) |
Current treatment for sarcoidosisa, n (%) | |
Adrenocorticotropin hormone analogue | 1 (9) |
Bronchodilators | 2 (18) |
Corticosteroids | 8 (73) |
Hydroxychloroquine | 0 |
Immunosuppressants (azathioprine) | 1 (9) |
Monoclonal antibodies (rituximab) | 1 (9) |
History of oxygen useb | 8 (73) |
WHO functional class, n (%) | |
II | 6 (55) |
III | 5 (45) |
FVC (%), mean (SD) | 58.1 (15.7) |
FEV1 (L), mean (SD) | 1.0 (0.4) |
Pulmonary arterial pressure (mmHg), mean (SD) | 35.6 (5.4) |
Comorbid conditionsa, n (%) | |
Anemia | 2 (18) |
Anxiety | 4 (36) |
Asthma | 4 (36) |
Atrial fibrillation | 4 (36) |
Congestive heart failure | 2 (18) |
Degenerative disk disease | 2 (18) |
Depression | 3 (27) |
Diabetes | 3 (27) |
With chronic complications | 1 (9) |
Without chronic complications | 2 (18) |
Gastroesophageal reflux disease | 1 (9) |
Hypertension | 6 (55) |
Hypersensitivity lung disease | 2 (18) |
Obstructive sleep apnea | 2 (18) |
Osteoporosis | 2 (18) |
Other health condition(s)c | 10 (91) |
None | 0 |